Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senhwa BiosciencesROCO:6492 -1.35%70 Altman Z2-Score is 16.38 as of Jul. 15, 2026, which is 48% below its 10-year median of 31.62. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,392 Biotechnology companies, Senhwa Biosciences ranks better than 90.95% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Senhwa Biosciences has a Altman Z2-Score of 16.38, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Senhwa Biosciences's Altman Z2-Score or its related term are showing as below:
ROCO:6492'
s Altman Z2-Score Range Over the Past 10 Years
Min: 16.38 Med: 31.62 Max: 45.67
Current: 16.38
During the past 13 years, Senhwa Biosciences's highest Altman Z2-Score was 45.67. The lowest was 16.38. And the median was 31.62.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Senhwa Biosciences Altman Z2-Score Related Terms
Senhwa Biosciences Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Senhwa Biosciences's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6492 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison
For the Biotechnology subindustry, Senhwa Biosciences's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senhwa Biosciences Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Senhwa Biosciences's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Senhwa Biosciences's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.8972
+
3.26
*
-0.3249
+
6.72
*
-0.3206
+
1.05
*
13.0525
=
16.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Senhwa Biosciences (ROCO:6492) has a Altman Z2-Score of 16.38 as of Jul. 15, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Senhwa Biosciences and its competitors. This is 48% below median its historical median of 31.62. Over the past decade, Senhwa Biosciences' Altman Z2-Score has ranged from 16.38 to 45.67. According to the industry distribution chart, Senhwa Biosciences ranks #126 out of 1392 companies in the Biotechnology industry, placing it in the top 9.1%.
Is Senhwa Biosciences' Altman Z2-Score too high?
Senhwa Biosciences' current Altman Z2-Score of 16.38 is 48% below median its 10-year median of 31.62. Over the past 10 years, this metric has ranged from a low of 16.38 to a high of 45.67. Based on the distribution chart, Senhwa Biosciences ranks #126 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Senhwa Biosciences ranks #126 out of 1392 companies for Altman Z2-Score. This places Senhwa Biosciences in the top 9% of its industry — outperforming the majority of peers. Historically, Senhwa Biosciences' own Altman Z2-Score has ranged from 16.38 to 45.67 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Senhwa Biosciences and its competitors. Senhwa Biosciences's current Altman Z2-Score is 16.38, which is 48% below median its own 10-year median of 31.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current Altman Z2-Score is 16.38, which is 48% below median its 10-year median of 31.62. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current Altman Z2-Score is 16.38 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?
Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued.
The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74.
GuruFocus considers Senhwa Biosciences to be Fairly Valued.
Key valuation signals for ROCO:6492:
Altman Z2-Score: 16.38 (48% below median its 10-year median of 31.62)
GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:6492
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6492 has been successfully added to your 
